Plain-English translation of NCT04680260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to help doctors decide what chemotherapy (if any) you need after surgery to remove colorectal cancer that has spread to other parts of your body. Instead of using standard guidelines alone, doctors will use a special blood test called ctDNA to look for cancer cells in your blood and guide treatment decisions. The goal is to match each patient with the right treatment—whether that's stronger chemotherapy, a gentler option, or no chemotherapy at all.
After surgery for advanced colorectal cancer, doctors typically give all patients the same chemotherapy treatment plan based on general guidelines. However, not every patient benefits equally, and some people experience unnecessary side effects. This trial hopes to personalize treatment by using the blood test to identify which patients actually need chemotherapy and which ones might do well without it.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either the standard treatment approach or the blood test–guided approach. In both cases, a blood sample will be taken after your surgery to check for cancer cells. If you are in the blood test group, your doctor will use those results to decide whether you need strong chemotherapy, a gentler single drug, or no chemotherapy at all. If you are in the standard group, your doctor will follow usual treatment guidelines. You will have regular follow-up visits and additional blood tests to monitor your health and watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Denmark